基因镜公司宣布,美国专利审判和上诉委员会(PTAB)的最新裁决,有力支持了该公司在相关专利争议中的长期法律立场。这一关键决定为旗下结直肠癌筛查产品Colosense的持续商业化进程消除了重要法律障碍,标志着公司在知识产权保护方面取得重大进展。
基因镜公司宣布,美国专利审判和上诉委员会(PTAB)的最新裁决,有力支持了该公司在相关专利争议中的长期法律立场。这一关键决定为旗下结直肠癌筛查产品Colosense的持续商业化进程消除了重要法律障碍,标志着公司在知识产权保护方面取得重大进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.